ELSEVIER

Diabetes Research and Clinical Practice 51 (2001) 227–229

DIABETES RESEARCH AND CLINICAL PRACTICE

www.elsevier.com/locate/diabres

Author index of volume 51

Adachi, H., Y. Hirai, M. Tsuruta, Y. Fujiura, T. Imaizuml, Is insulin resistance or diabetes mellitus associated with stroke?: An 18-year follow-up study **51**, 215
Agarwal, M.M., P.F. Hughes, J. Punnose, M. Ezimokhai, L. Thomas, Gestational diabetes screening of a multiethnic, high-risk population using glycated proteins **51**, 67
Ahmed, I., M.S. Lakhani, M. Gillett, A. John, H. Raza, Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic *Momordica charantia* (karela) fruit extract in streptozotocin-induced diabetic rats **51**, 155
Akanuma, Y., see Yoshida, Y. **51**, 195
Ashok, S., see Govindarajan, M. **51**, 29

Barberio, S., see Bruttomesso, D. **51**, 97
Bashir, M.I., see Zargar, A.H. **51**, 145
Benjasuratwong, Y., see Puavilai, G. **51**, 125
Borg, H., see Samuelsson, U. **51**, 51
Bruttomesso, D., C. Fongher, B. Silvestri, S. Barberio, M.C. Marescotti, E. Iori, A. Valerio, D. Crazzolara, A. Pianta, A. Tiengo, S. Del Prato, Combination of continuous subcutaneous infusion of insulin and octreotide in Type 1 diabetic patients **51**, 97

Chanprasertyotin, S., see Puavilai, G. **51**, 125
Chantraraprasert, S., see Puavilai, G. **51**, 125
Chen, C.-J., see Chen, K.-T. **51**, 59
Chen, K.-T., C.-J. Chen, E.W. Gregg, M.M. Engelgau, K.M. Venkat Narayan, Prevalence of type 2 diabetes mellitus in Taiwan: ethnic variation and risk factors **51**, 59
Chew, L.S., see Tan, C.E. **51**, 107
Chiang, S.-C., see Hwu, C.-M. **51**, 187
Chio, L.F., see Tan, C.E. **51**, 107
Chung, J.-H., see Jeong, I.-K. **51**, 163
Crazzolara, D., see Bruttomesso, D. **51**, 97

Dar, F.A., see Zargar, A.H. **51**, 145
Deepa, R., see Govindarajan, M. **51**, 29
Deerochochanawong, C., see Puavilai, G. **51**, 125
Del Prato, S., see Bruttomesso, D. **51**, 97
Di Mauro, M., G. Papalia, R. Le Moli, B. Nativo, F. Nicoletti, M. Lunetta, Effect of octreotide on insulin requirement, hepatic glucose production, growth hormone, glucagon and c-peptide levels in type 2 diabetic patients with chronic renal failure or normal renal function **51**, 45

Engelgau, M.M., see Chen, K.-T. **51**, 59
Eng, H.K., see Tan, C.E. **51**, 107
Ezimokhai, M., see Agarwal, M.M. **51**, 67

Fernlund, P., see Samuelsson, U. **51**, 51
Fongher, C., see Bruttomesso, D. **51**, 97
Fujita, H., see Kawai, T. **51**, 1
Fujiura, Y., see Adachi, H. **51**, 215
Fukae, S., see Matsumoto, K. **51**, 181

Gillett, M., see Ahmed, I. **51**, 155
Govindarajan, M., V. Mohan, R. Deepa, S. Ashok, C.S. Pitchumoni, Histopathology and immunohistochemistry of pancreatic islets in fibrocalculous pancreatic diabetes **51**, 29
Gregg, E.W., see Chen, K.-T. **51**, 59
Grześkowiak, E., see Mikrut, K. **51**, 79

Hagura, R., see Yoshida, Y. **51**, 195
Hamada, Y., see Nakamura, J. **51**, 9
Hanefeld, M., see Standl, E. **51**, 205
Hänninen, J., J. Takala, S. Keinänen-Kiukaanniemi, Good continuity of care may improve quality of life in Type 2 diabetes **51**, 21
Hara, T., see Nakamura, J. **51**, 9
Hara, Y., see Yoshida, Y. **51**, 195
Hirai, Y., see Adachi, H. **51**, 215
Hirose, H., see Kawai, T. **51**, 1
Ho, L.-T., see Hwu, C.-M. **51**, 187
Hotta, N., see Nakamura, J. **51**, 9
Hsiao, L.-C., see Hwu, C.-M. **51**, 187
Hughes, P.F., see Agarwal, M.M. **51**, 67

PII: S0168-8227(00)00224-8

Hwu, C.-M., C.F. Kwok, S.-C. Chiang, P.-Y. Wang, L.-C. Hsiao, S.-H. Lee, S.-H. Lin, L.-T. Ho, A comparison of insulin suppression tests performed with somatostatin and octreotide with particular reference to tolerability **51**, 187

Imaizuml, T., see Adachi, H. **51**, 215
Inada, H., see Kimura, K. **51**, 173
Iori, E., see Bruttomesso, D. **51**, 97

Jayakumar, L., see Tan, C.E. **51**, 107
Jenkins, D.J.A., see Sievenpiper, J.L. **51**, 87
Jeong, I.-K., S.-H. Oh, B.-J. Kim, J.-H. Chung, Y.-K. Min, M.-S. Lee, M.-K. Lee, K.-W. Kim, The effects of dexamethasone on insulin release and biosynthesis are dependent on the dose and duration of treatment **51**, 163
John, A., see Ahmed, I. **51**, 155
Josse, R.G., see Sievenpiper, J.L. **51**, 87

Kadotani, S., see Kimura, K. **51**, 173
Kamijo, M., see Nakamura, J. **51**, 9
Kawai, T., H. Hirose, Y. Seto, H. Fujita, T. Saruta, Chronic effects of different fatty acids and leptin in INS-1 cells **51**, 1
Kawamori, R., see Yoshii, H. **51**, 115
Kawamura, T., see Kimura, K. **51**, 173
Keinänen-Kiukaanniemi, S., see Hänninen, J. **51**, 21
Kespechara, K., see Puavilai, G. **51**, 125
Khan, A.K., see Zargar, A.H. **51**, 145
Kheesukapan, P., see Puavilai, G. **51**, 125
Kim, B.-J., see Jeong, I.-K. **51**, 163
Kim, K.-W., see Jeong, I.-K. **51**, 163
Kimura, K., T. Kawamura, S. Kadotani, H. Inada, S. Niihira, T. Yamano, Peptide-specific cytotoxicity of T lymphocytes against glutamic acid decarboxylase and insulin in type 1 diabetes mellitus **51**, 173
Kizaki, Y., see Matsumoto, K. **51**, 181
Koh, N., see Nakamura, J. **51**, 9
Koźlik, J., see Mikrut, K. **51**, 79
Krauss, H., see Mikrut, K. **51**, 79
Kwok, C.F., see Hwu, C.-M. **51**, 187

Lakhani, M.S., see Ahmed, I. **51**, 155
Laway, B.A., see Zargar, A.H. **51**, 145
Lee, M.-K., see Jeong, I.-K. **51**, 163
Lee, M.-S., see Jeong, I.-K. **51**, 163
Lee, S.-H., see Hwu, C.-M. **51**, 187
Le Moli, R., see Di Mauro, M. **51**, 45
Lim, H.S., see Tan, C.E. **51**, 107
Lim, S.C., see Tan, C.E. **51**, 107
Lin, S.-H., see Hwu, C.-M. **51**, 187
Ludvigsson, J., see Samuelsson, U. **51**, 51
Lunetta, M., see Di Mauro, M. **51**, 45

Marescotti, M.C., see Bruttomesso, D. **51**, 97
Masoodi, S.R., see Zargar, A.H. **51**, 145
Matsumoto, K., Y. Kizaki, S. Fukae, M. Tomihira, Y. Sera, Y. Ueki, T. Tominaga, S. Miyake, Insulin resistance and coronary risk factors in Japanese type 2 diabetic patients with definite coronary artery disease **51**, 181
Mikrut, K., J. Paluszak, J. Koźlik, P. Sosnowski, H. Krauss, E. Grześkowiak, The effect of bradykinin on the oxidative state of rats with acute hyperglycaemia **51**, 79
Min, Y.-K., see Jeong, I.-K. **51**, 163
Misumi, S., see Nagai, T. **51**, 39
Mita, Y., see Nagai, T. **51**, 39
Miyake, S., see Matsumoto, K. **51**, 181
Mohan, V., see Govindarajan, M. **51**, 29
Montreewasuwat, N., see Puavilai, G. **51**, 125
Mori, K., see Nakamura, J. **51**, 9
Mori, M., see Nagai, T. **51**, 39
Munsakul, N., see Puavilai, G. **51**, 125

Naditch, L., see Standl, E. **51**, 205
Nagai, T., T. Tomizawa, N. Tonooka, Y. Mita, S. Misumi, M. Mori, Diabetes mellitus with left transverse sinus thrombosis and right transverse sinus aplasia **51**, 39
Nakamura, J., Y. Hamada, F. Sakakibara, T. Hara, T. Wakao, K. Mori, E. Nakashima, K. Naruse, M. Kamijo, N. Koh, N. Hotta, Physiological and morphometric analyses of neuropathy in sucrose-fed OLETF rats **51**, 9
Nakashima, E., see Nakamura, J. **51**, 9
Naruse, K., see Nakamura, J. **51**, 9
Nativo, B., see Di Mauro, M. **51**, 45
Nicoletti, F., see Di Mauro, M. **51**, 45
Niihira, S., see Kimura, K. **51**, 173
Nitiyanant, W., see Puavilai, G. **51**, 125

Ohmura, C., see Yoshii, H. **51**, 115
Oh, S.-H., see Jeong, I.-K. **51**, 163

Packard, C.J., see Tan, C.E. **51**, 107
Paluszak, J., see Mikrut, K. **51**, 79
Papalia, G., see Di Mauro, M. **51**, 45
Pianta, A., see Bruttomesso, D. **51**, 97
Pibernik-Okanović, M., Psychometric properties of the World Health Organisation quality of life questionnaire (WHO-QOL-100) in diabetic patients in Croatia **51**, 133
Pitchumoni, C.S., see Govindarajan, M. **51**, 29
Pongchaiyaikul, C., see Puavilai, G. **51**, 125
Puavilai, G., P. Kheesukapan, S. Chanprasertyotin, S. Chantraraprasert, S. Suwanvilaikorn, W. Nitiyanant, C. Deerochochanawong, Y. Benjasuratwong, N. Munsakul, C. Pongchaiyaikul, K. Kespechara, N. Montreewasuwat, Random capillary plasma glucose measurement in the screening of diabetes mellitus in high-risk subjects in Thailand **51**, 125
Punnose, J., see Agarwal, M.M. **51**, 67

Raptis, S.A., see Standl, E. **51**, 205
Raza, H., see Ahmed, I. **51**, 155
Rybka, J., see Standl, E. **51**, 205

Sakakibara, F., see Nakamura, J. **51**, 9
Samuelsson, U., G. Sundkvist, H. Borg, P. Fernlund, J. Ludvigsson, Islet autoantibodies in the prediction of diabetes in school children **51**, 51
Saruta, T., see Kawai, T. **51**, 1
Schernthaner, G., see Standl, E. **51**, 205
Sera, Y., see Matsumoto, K. **51**, 181
Seto, Y., see Kawai, T. **51**, 1
Sievenpiper, J.L., D.J.A. Jenkins, R.G. Josse, V. Vuksan, Dilution of the 75-g oral glucose tolerance test improves overall tolerability but not reproducibility in subjects with different body compositions **51**, 87
Silvestri, B., see Bruttomesso, D. **51**, 97
Sosnowski, P., see Mikrut, K. **51**, 79
Standl, E., G. Schernthaner, J. Rybka, M. Hanefeld, S.A. Raptis, L. Naditch, Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics **51**, 205
Sugasawa, G., see Yoshida, Y. **51**, 195
Sundkvist, G., see Samuelsson, U. **51**, 51
Suwanvilaikorn, S., see Puavilai, G. **51**, 125

Tai, E.S., see Tan, C.E. **51**, 107
Takala, J., see Hänninen, J. **51**, 21
Tanaka, Y., see Yoshii, H. **51**, 115
Tan, C.E., L.S. Chew, L.F. Chio, E.S. Tai, H.S. Lim, S.C. Lim, L. Jayakumar, H.K. Eng, C.J. Packard, Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control **51**, 107
Thomas, L., see Agarwal, M.M. **51**, 67
Tiengo, A., see Bruttomesso, D. **51**, 97
Tomihira, M., see Matsumoto, K. **51**, 181
Tominaga, T., see Matsumoto, K. **51**, 181
Tomizawa, T., see Nagai, T. **51**, 39
Tonooka, N., see Nagai, T. **51**, 39
Tsuruta, M., see Adachi, H. **51**, 215

Uchino, H., see Yoshii, H. **51**, 115
Ueki, Y., see Matsumoto, K. **51**, 181

Valerio, A., see Bruttomesso, D. **51**, 97
Venkat Narayan, K.M., see Chen, K.-T. **51**, 59
Vuksan, V., see Sievenpiper, J.L. **51**, 87

Wakao, T., see Nakamura, J. **51**, 9
Wang, P.-Y., see Hwu, C.-M. **51**, 187
Wani, A.I., see Zargar, A.H. **51**, 145
Watanabe, K., see Yoshii, H. **51**, 115

Yamano, T., see Kimura, K. **51**, 173
Yoshida, Y., R. Hagura, Y. Hara, G. Sugasawa, Y. Akanuma, Risk factors for the development of diabetic retinopathy in Japanese type 2 diabetic patients **51**, 195
Yoshii, H., H. Uchino, C. Ohmura, K. Watanabe, Y. Tanaka, R. Kawamori, Clinical usefulness of measuring urinary polyol excretion by gas-chromatography/mass-spectrometry in type 2 diabetes to assess polyol pathway activity **51**, 115

Zargar, A.H., S.R. Masoodi, A.K. Khan, M.I. Bashir, B.A. Laway, A.I. Wani, F.A. Dar, Impaired fasting glucose and impaired glucose tolerance — lack of agreement between the two categories in a North Indian population **51**, 145

ELSEVIER

Diabetes Research and Clinical Practice 51 (2001) 231–234

DIABETES RESEARCH AND CLINICAL PRACTICE

www.elsevier.com/locate/diabres

Subject index of volume 51

Acceptability; Volume; OGTT; Glucose; Insulin; Intrasubject variation; Palatability **51**, 87

Acute hyperglycaemia; Oxidative stress; Free radicals; Bradykinin **51**, 79

Aldose reductase inhibitor; Sucrose; Otsuka Long–Evans Tokushima fatty rat; Diabetic neuropathy; Fiber size **51**, 9

Anti-coagulant therapy; Hypercoagulation; Diabetes mellitus **51**, 39

Autoantibodies; Type 1 diabetes; Prediction; Schoolchildren **51**, 51

Blood glucose control; Retinopathy; Type 2 diabetes **51**, 195

Blood glucose control; Type 2 diabetes; Quality of life; Diabetes care **51**, 21

Bradykinin; Acute hyperglycaemia; Oxidative stress; Free radicals **51**, 79

Cardiovascular risk; Glycaemic control; LDL subfraction; Diabetic dyslipidaemia **51**, 107

Cerebrvascular disease; Insulin; Glucose; Prospective study **51**, 215

Cholesterol; Lipid peroxidation; *Momordica charantia*; Rat; Streptozotocin-induced diabetes; Triglycerides **51**, 155

Chronic renal failure; Octreotide; Non-insulin-dependent diabetes mellitus; Hepatic glucose production; Insulin requirement **51**, 45

Continuous subcutaneous insulin infusion; Type 1 diabetes; Continuous subcutaneous octreotide infusion; Insulin resistance; Counterregulatory hormones **51**, 97

Continuous subcutaneous octreotide infusion; Type 1 diabetes; Continuous subcutaneous insulin infusion; Insulin resistance; Counterregulatory hormones **51**, 97

Coronary artery disease; Insulin resistance; Type 2 diabetes mellitus; Insulin tolerance test; Insulin resistance syndrome **51**, 181

Counterregulatory hormones; Type 1 diabetes; Continuous subcutaneous insulin infusion; Continuous subcutaneous octreotide infusion; Insulin resistance **51**, 97

Cytotoxic T cell; Type 1 diabetes; Insulin; HLA-A24 **51**, 173

Dexamethasone; Insulin release; Insulin biosynthesis **51**, 163

Diabetes care; Type 2 diabetes; Quality of life; Blood glucose control **51**, 21

Diabetes mellitus; Hypercoagulation; Anti-coagulant therapy **51**, 39

Diabetes mellitus; Random capillary blood glucose; Screening; Oral glucose tolerance test **51**, 125

Diabetic dyslipidaemia; Glycaemic control; LDL subfraction; Cardiovascular risk **51**, 107

Diabetic neuropathy; Sucrose; Otsuka Long–Evans Tokushima fatty rat; Fiber size; Aldose reductase inhibitor **51**, 9

Diabetic patients; Quality of life assessment; Psychometric properties **51**, 133

Endocrine pancreas; Fibrocalculous pancreatic diabetes; Tropical chronic pancreatitis; Pathology; Immunohistochemistry; Exocrine; Ketosis resistance **51**, 29

Environmental factor; Type 2 diabetes mellitus; Risk factor; Genetic factor **51**, 59

PII: S0168-8227(00)00225-X

Exocrine; Fibrocalculous pancreatic diabetes; Tropical chronic pancreatitis; Pathology; Immunohistochemistry; Endocrine pancreas; Ketosis resistance **51**, 29

Fiber size; Sucrose; Otsuka Long–Evans Tokushima fatty rat; Diabetic neuropathy; Aldose reductase inhibitor **51**, 9

Fibrocalculous pancreatic diabetes; Tropical chronic pancreatitis; Pathology; Immunohistochemistry; Exocrine; Endocrine pancreas; Ketosis resistance **51**, 29

Free fatty acid; Lipotoxicity; Leptin; INS-1 cell; MTT assay **51**, 1

Free radicals; Acute hyperglycaemia; Oxidative stress; Bradykinin **51**, 79

Fructosamine; Gestational diabetes; Screening; Glycated hemoglobin **51**, 67

Genetic factor; Type 2 diabetes mellitus; Risk factor; Environmental factor **51**, 59

Gestational diabetes; Screening; Glycated hemoglobin; Fructosamine **51**, 67

Glucose; Insulin; Cerebrvascular disease; Prospective study **51**, 215

Glucose; Volume; OGTT; Insulin; Intrasubject variation; Acceptability; Palatability **51**, 87

α-Glucosidase inhibitor; Type 2 diabetes; Miglitol; Sulphonylurea; Metformin **51**, 205

Glycaemic control; LDL subfraction; Cardiovascular risk; Diabetic dyslipidaemia **51**, 107

Glycated hemoglobin; Gestational diabetes; Screening; Fructosamine **51**, 67

Hepatic glucose production; Octreotide; Non-insulin-dependent diabetes mellitus; Chronic renal failure; Insulin requirement **51**, 45

HLA-A24; Type 1 diabetes; Cytotoxic T cell; Insulin **51**, 173

Hypercoagulation; Anti-coagulant therapy; Diabetes mellitus **51**, 39

Immunohistochemistry; Fibrocalculous pancreatic diabetes; Tropical chronic pancreatitis; Pathology; Exocrine; Endocrine pancreas; Ketosis resistance **51**, 29

Impaired fasting glucose; Impaired glucose tolerance; Type 2 diabetes; Prevalence **51**, 145

Impaired glucose tolerance; Impaired fasting glucose; Type 2 diabetes; Prevalence **51**, 145

INS-1 cell; Lipotoxicity; Free fatty acid; Leptin; MTT assay **51**, 1

Insulin biosynthesis; Dexamethasone; Insulin release **51**, 163

Insulin; Glucose; Cerebrvascular disease; Prospective study **51**, 215

Insulin release; Dexamethasone; Insulin biosynthesis **51**, 163

Insulin requirement; Octreotide; Non-insulin-dependent diabetes mellitus; Chronic renal failure; Hepatic glucose production **51**, 45

Insulin resistance syndrome; Insulin resistance; Type 2 diabetes mellitus; Coronary artery disease; Insulin tolerance test **51**, 181

Insulin resistance; Type 1 diabetes; Continuous subcutaneous insulin infusion; Continuous subcutaneous octreotide infusion; Counterregulatory hormones **51**, 97

Insulin resistance; Type 2 diabetes mellitus; Coronary artery disease; Insulin tolerance test; Insulin resistance syndrome **51**, 181

Insulin suppression test; Octreotide; Somatostatin; Tolerability **51**, 187

Insulin tolerance test; Insulin resistance; Type 2 diabetes mellitus; Coronary artery disease; Insulin resistance syndrome **51**, 181

Insulin; Type 1 diabetes; Cytotoxic T cell; HLA-A24 **51**, 173

Insulin; Volume; OGTT; Glucose; Intrasubject variation; Acceptability; Palatability **51**, 87

Intrasubject variation; Volume; OGTT; Glucose; Insulin; Acceptability; Palatability **51**, 87

Ketosis resistance; Fibrocalculous pancreatic diabetes; Tropical chronic pancreatitis; Pathology; Immunohistochemistry; Exocrine; Endocrine pancreas **51**, 29

LDL subfraction; Glycaemic control; Cardiovascular risk; Diabetic dyslipidaemia **51**, 107

Leptin; Lipotoxicity; Free fatty acid; INS-1 cell; MTT assay **51**, 1

Lipid peroxidation; Cholesterol; *Momordica charantia*; Rat; Streptozotocin-induced diabetes; Triglycerides **51**, 155

Lipotoxicity; Free fatty acid; Leptin; INS-1 cell; MTT assay **51**, 1

Metformin; Type 2 diabetes; α-Glucosidase inhibitor; Miglitol; Sulphonylurea **51**, 205

Miglitol; Type 2 diabetes; α-Glucosidase inhibitor; Sulphonylurea; Metformin **51**, 205

Momordica charantia; Cholesterol; Lipid peroxidation; Rat; Streptozotocin-induced diabetes; Triglycerides **51**, 155

MTT assay; Lipotoxicity; Free fatty acid; Leptin; INS-1 cell **51**, 1

Myo-inositol; Polyol pathway activity; Urinary polyols **51**, 115

Non-insulin-dependent diabetes mellitus; Octreotide; Chronic renal failure; Hepatic glucose production; Insulin requirement **51**, 45

Octreotide; Insulin suppression test; Somatostatin; Tolerability **51**, 187

Octreotide; Non-insulin-dependent diabetes mellitus; Chronic renal failure; Hepatic glucose production; Insulin requirement **51**, 45

OGTT; Volume; Glucose; Insulin; Intrasubject variation; Acceptability; Palatability **51**, 87

Oral glucose tolerance test; Random capillary blood glucose; Diabetes mellitus; Screening **51**, 125

Otsuka Long–Evans Tokushima fatty rat; Sucrose; Diabetic neuropathy; Fiber size; Aldose reductase inhibitor **51**, 9

Oxidative stress; Acute hyperglycaemia; Free radicals; Bradykinin **51**, 79

Palatability; Volume; OGTT; Glucose; Insulin; Intrasubject variation; Acceptability **51**, 87

Pathology; Fibrocalculous pancreatic diabetes; Tropical chronic pancreatitis; Immunohistochemistry; Exocrine; Endocrine pancreas; Ketosis resistance **51**, 29

Polyol pathway activity; Myo-inositol; Urinary polyols **51**, 115

Prediction; Autoantibodies; Type 1 diabetes; Schoolchildren **51**, 51

Prevalence; Impaired glucose tolerance; Impaired fasting glucose; Type 2 diabetes **51**, 145

Prospective study; Insulin; Glucose; Cerebrvascular disease **51**, 215

Psychometric properties; Quality of life assessment; Diabetic patients **51**, 133

Quality of life assessment; Psychometric properties; Diabetic patients **51**, 133

Quality of life; Type 2 diabetes; Diabetes care; Blood glucose control **51**, 21

Random capillary blood glucose; Diabetes mellitus; Screening; Oral glucose tolerance test **51**, 125

Rat; Cholesterol; Lipid peroxidation; *Momordica charantia*; Streptozotocin-induced diabetes; Triglycerides **51**, 155

Retinopathy; Blood glucose control; Type 2 diabetes **51**, 195

Risk factor; Type 2 diabetes mellitus; Genetic factor; Environmental factor **51**, 59

Schoolchildren; Autoantibodies; Type 1 diabetes; Prediction **51**, 51

Screening; Gestational diabetes; Glycated hemoglobin; Fructosamine **51**, 67

Screening; Random capillary blood glucose; Diabetes mellitus; Oral glucose tolerance test **51**, 125

Somatostatin; Insulin suppression test; Octreotide; Tolerability **51**, 187

Streptozotocin-induced diabetes; Cholesterol; Lipid peroxidation; *Momordica charantia*; Rat; Triglycerides **51**, 155

Sucrose; Otsuka Long–Evans Tokushima fatty rat; Diabetic neuropathy; Fiber size; Aldose reductase inhibitor **51**, 9

Sulphonylurea; Type 2 diabetes; α-Glucosidase inhibitor; Miglitol; Metformin **51**, 205

Tolerability; Insulin suppression test; Octreotide; Somatostatin **51**, 187

Triglycerides; Cholesterol; Lipid peroxidation; *Momordica charantia*; Rat; Streptozotocin-induced diabetes **51**, 155

Tropical chronic pancreatitis; Fibrocalculous pancreatic diabetes; Pathology; Immunohistochemistry; Exocrine; Endocrine pancreas; Ketosis resistance **51**, 29

Type 1 diabetes; Autoantibodies; Prediction; Schoolchildren **51**, 51

Type 1 diabetes; Continuous subcutaneous insulin infusion; Continuous subcutaneous octreotide infusion; Insulin resistance; Counterregulatory hormones **51**, 97

Type 1 diabetes; Cytotoxic T cell; Insulin; HLA-A24 **51**, 173

Type 2 diabetes; α-Glucosidase inhibitor; Miglitol; Sulphonylurea; Metformin **51**, 205

Type 2 diabetes; Impaired glucose tolerance; Impaired fasting glucose; Prevalence **51**, 145

Type 2 diabetes mellitus; Insulin resistance; Coronary artery disease; Insulin tolerance test; Insulin resistance syndrome **51**, 181

Type 2 diabetes mellitus; Risk factor; Genetic factor; Environmental factor **51**, 59

Type 2 diabetes; Quality of life; Diabetes care; Blood glucose control **51**, 21

Type 2 diabetes; Retinopathy; Blood glucose control **51**, 195

Urinary polyols; Myo-inositol; Polyol pathway activity **51**, 115

Volume; OGTT; Glucose; Insulin; Intrasubject variation; Acceptability; Palatability **51**, 87